Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextilidine is the (1S,2R)-enantiomer of the synthetic opioid analgesic tilidine. It functions as a prodrug that undergoes rapid first-pass metabolism in the liver, primarily via N-demethylation by CYP3A4 and CYP2C19 enzymes, to form its active metabolite, nortilidine. Nortilidine is a potent agonist of the μ-opioid receptor and is responsible for the moderate to strong analgesic effects associated with tilidine administration. In clinical practice, dextilidine is typically administered as part of the racemic mixture tilidine, which is often formulated in combination with naloxone to prevent parenteral abuse.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextilidine.